Pharmacologic characteristics of rhTPO and PEG-rHuMGDF
| Characteristic . | rhTPO . | PEG-rHuMGDF . |
|---|---|---|
| Terminalt1/2(h) | 24-40 | 31 |
| Kd for c-Mp1 (pM) | 150 | 150 |
| Platelet clearance (mL/h/109) | 1.28 | 1.28 |
| Time to onset of effect in mice (d) | 3 | 3 |
| Time to peak effect in mice (d) | 4-6 | 4-6 |
| Truncation | No | Yes |
| Glycosylation | Yes | No |
| Pegylation | No | Yes |
| Human route tested | Intravenous | Subcutaneous |
| Characteristic . | rhTPO . | PEG-rHuMGDF . |
|---|---|---|
| Terminalt1/2(h) | 24-40 | 31 |
| Kd for c-Mp1 (pM) | 150 | 150 |
| Platelet clearance (mL/h/109) | 1.28 | 1.28 |
| Time to onset of effect in mice (d) | 3 | 3 |
| Time to peak effect in mice (d) | 4-6 | 4-6 |
| Truncation | No | Yes |
| Glycosylation | Yes | No |
| Pegylation | No | Yes |
| Human route tested | Intravenous | Subcutaneous |
PEG-rHuMGDF, pegylated recombinant human megakaryocyte growth and development factor; rhTPO, recombinant human thrombopoietin.